164 filings
8-K
ABBV
Abbvie Inc
3 Apr 24
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
4:06pm
8-K
ABBV
Abbvie Inc
26 Feb 24
Other Events
5:08pm
8-K
ABBV
Abbvie Inc
20 Feb 24
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
9:00am
8-K
ABBV
Abbvie Inc
12 Feb 24
AbbVie Completes Acquisition of ImmunoGen
7:49am
8-K
ABBV
Abbvie Inc
2 Feb 24
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
7:51am
8-K
t55xb 439r
5 Jan 24
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
4:03pm
8-K
8pxw0qzl65r qt3h058
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
ajfaap7
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHEREĀ® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
8-K
f6u t0i8y
27 Oct 23
AbbVie Reports Third-Quarter 2023 Financial Results
7:49am
8-K
pagsbt 9sbq38fht0
12 Oct 23
Departure of Directors or Certain Officers
5:17pm
8-K
ajt073bmhx8y
4 Oct 23
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
4:11pm
8-K
9tx7v 250dyl4l
27 Jul 23
AbbVie Reports Second-Quarter 2023 Financial Results
7:45am
8-K
o2cirvr
6 Jul 23
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
4:18pm
8-K
jjb57s 2rxgve
29 Jun 23
Departure of Directors or Certain Officers
5:00pm
8-K
x1ha7qgm1nhvhkz8ri
10 May 23
Submission of Matters to a Vote of Security Holders
5:10pm
8-K
5vpnesu
27 Apr 23
AbbVie Reports First-Quarter 2023 Financial Results
7:36am
8-K
aeyfcy55dfssgs
5 Apr 23
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
4:33pm
8-K
ri6czfwj
28 Mar 23
Entry into a Material Definitive Agreement
4:37pm
8-K
68ctnpt70
9 Feb 23
AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results
7:55am
8-K
xdyl711msto8
10 Jan 23
Regulation FD Disclosure
8:15am